Eli Lilly agreed to acquire Adverum in a deal focused on ixoberogene soroparvovec (ixo‑vec), a Phase III one‑time gene therapy for wet age‑related macular degeneration, and separately announced a partnership with Nvidia to build what the companies call the most powerful pharmaceutical supercomputer. Lilly said it pursued the whole‑company purchase to secure the gene‑therapy program and retain the Adverum team to advance the Phase III program. The Nvidia collaboration will provide GPU‑accelerated infrastructure and AI tools to scale drug‑discovery models and virtual cell simulations. Together, the transactions signal Lilly’s dual strategy: expand its sensory/ophthalmology pipeline through targeted M&A and invest heavily in AI compute to accelerate discovery and development across therapeutic areas.